Home
About Us
Membership
Member Biography

Member Biography

Lisa M. Landrum, MD, PhD

Lisa M. Landrum, M.D., Ph.D.

Phone: (317) 944-0332
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
UH 2440
Indianapolis, IN 46202
Fax: (317) 968-1118

Faculty appointments

Mary Fendrich Hulman Professor of Gynecologic Oncology, Department of Obstetrics and Gynecology, IU School of Medicine
Chair, Department of Obstetrics and Gynecology
Professor of Obstetrics & Gynecology, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, IU School of Medicine
Full member, Experimental and Developmental Therapeutics

Current research interests in determining best adjuvant therapy for early stage high-intermediate endometrial cancer using combination of immunotherapy, chemotherapy and radiation. Also strong interest in disparities in screening as well as evaluation & management of cervical cancer which results in poorer survival outcomes. Collaboration with U of Oklahoma looking at how adverse childhood experiences (ACEs) impact diagnosis and treatment of women with cervical cancer. Also interested in supportive/palliative care for patients as well as enhancing communication skills for physicians. Collaboration with Joan Walker, MD at U of Oklahoma and NCORP is in the early stages.

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053). CTO-GOG-3053

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or CarcinosarcomaCTO-NRG-GY026

A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial CancerCTO-NRG-GY028

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (ASCENT-GYN-01)CTO-GOG-3104

A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine LeiomyosarcomaCTO-GOG-3088

A PHASE III TRIAL OF THE IMPACT OF SENTINEL LYMPH NODE MAPPING ON PATIENT REPORTED LOWER EXTREMITY LIMB DYSFUNCTION IN ENDOMETRIAL CANCERCTO-NRG-CC010

Simon Says Expert Series featuring Lisa Landrum

Ovarian Cancer: Understanding Risk Factors, Diagnosis & Treatment

September 2024

#ResearchCuresCancer

Support Our Research